Febuxostat use falls short of predictions in chronic gout

Two years after its listing for second-line treatment in gout, a PBS review has found that febuxostat is being used less than expected. In a predicted versus actual utilisation audit for febuxostat in the treatment of chronic gout, the Drug Utilisation Sub-Committee (DUSC) has found that the number of patients supplied febuxostat was 2,421 in ...

Already a member?

Enter your email to keep reading.